PGD2 Cancer Research Results

PGD2, prostaglandin D2: Click to Expand ⟱
Source:
Type:
PGD2 is one of several prostaglandins produced through the cyclooxygenase (COX) pathway, primarily via the action of hematopoietic and lipocalin-type prostaglandin D synthases (HPGDS and L-PGDS, respectively). It plays roles in inflammation, immune modulation, and cellular signals that can influence tumor development and progression.

PGD2 is a prostaglandin with complex roles in cancer biology, mediating processes such as inflammation, immune modulation, and cellular differentiation. In various cancers—including breast, prostate, colorectal, lung, and ovarian cancers—alterations in PGD2 production or PGD2 synthase expression have been reported. Often, higher PGD2 signaling correlates with more favorable outcomes, likely through mechanisms involving anti-inflammatory, pro-differentiation, and pro-apoptotic effects. However, the effects of PGD2 can be context-dependent.
Scientific Papers found: Click to Expand⟱
6908- FIS,    Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice
- in-vivo, AD, NA
*memory↑, We show here that oral administration of fisetin to APPswe/PS1dE9 double transgenic AD mice from 3 to 12 months of age prevents the development of learning and memory deficits.
*p‑ERK↑, This correlates with an increase in ERK phosphorylation along with a decrease in protein carbonylation, a marker of oxidative stress.
*CDK5↓, fisetin also reduces the levels of the cyclin-dependent kinase 5 (Cdk5) activator p35 cleavage product, p25, in both control and AD brains.
*P21↓,
*cognitive↑, Given the clear improvement in both cognitive and neuropsychiatric behavior in the AD mice fed fisetin
*ROS↓, Previously, it was shown that fisetin is able to reduce markers of oxidative stress in cell culture neuroprotection assays
*COX2/PTGS2↓, cyclooxygenase 2 (Cox2) and 12-lipoxygenase (12-LOX) was reduced by treatment with fisetin
*12LOX↓,
PGD2↓, fisetin increased production of prostaglandin D2 (PGD2)

1162- PI,    Piperine Inhibits the Activities of Platelet Cytosolic Phospholipase A2 and Thromboxane A2 Synthase without Affecting Cyclooxygenase-1 Activity: Different Mechanisms of Action Are Involved in the Inhibition of Platelet Aggregation and Macrophage Inflammatory Response
- in-vitro, NA, NA
*cPLA2↓, attenuating cPLA2 activity in collagen-stimulated platelets.
TXA2↓, results suggest that piperine inhibits platelet aggregation by attenuating cPLA2 and TXA2 synthase activities, rather than through the inhibition of COX-1 activity
COX2/PTGS2↓,
PGE2↓,
PGD2↓,


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Angiogenesis & Vasculature(tgid=14) ⓘ

TXA2↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   PGD2↓, 2,   PGE2↓, 1,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   cPLA2↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑ERK↑, 1,  

Migration(tgid=13) ⓘ

CDK5↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 1,   memory↑, 1,  
Total Targets: 9

Scientific Paper Hit Count for: PGD2, prostaglandin D2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1029  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page